BioSpace News Archive

Annovis Bio Inc. today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap.

Moon Surgical , a French-American pioneer in surgical innovation, announced today the United States Food and Drug Administration (FDA) clearance for the commercial version of its unique Maestro surgical system.

Amneal Pharmaceuticals, Inc. announced the continued expansion of its injectables portfolio with six new injectable product launches during the second quarter of 2024, bringing the Company’s total number of commercial injectable products available for the U.S. institutional market to over 40.

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will participate in a fireside chat at the 45th Annual Goldman Sachs Global Healthcare Conference to take place June 10-13, 2024.

According to the Skin Cancer Foundation, 90% of skin aging is caused by the sun,1 and even with proper SPF usage, harmful UV rays can still penetrate the skin.

Neuros Medical, Inc. today announced the appointment of Zach Stassen , Chief Financial Officer (CFO); Kirk Ellis, Vice President of U.S. Sales; and Steve Bosrock, Vice President of Marketing.

Sensome, the pioneer of microsensing technology for instant intra-operative tissue analysis, today announced positive results from its first-in-human CLOT OUT clinical trial evaluating the safety and performance of its Clotild® Smart Guidewire System used during mechanical thrombectomy treating ischemic stroke.

Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that the Company will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 2:00 p.m. ET in Miami, FL.

Eupraxia Pharmaceuticals Inc. today announced that results from its Phase 2 study of EP-104IAR for the treatment of osteoarthritis of the knee will be presented at the upcoming European Alliance of Associations for Rheumatology (“EULAR”) European Congress of Rheumatology 2024 (the “Meeting”).

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024.